Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

References

• LlovetJMRicciSMazzaferroVSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver, European Organisation For Research And Treatment Of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinomaJ Hepatol201256490894322424438
   PubMed Web of Science ®Google Scholar
• WelkerMWTrojanJAntiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safetyCancer Manag Res2013533734724204170
   PubMedGoogle Scholar
• ChengALKangYKLinDYSunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trialJ Clin Oncol201331324067407524081937
   PubMed Web of Science ®Google Scholar
• LlovetJMDecaensTRaoulJLBrivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJ Clin Oncol201331283509351623980090
   PubMed Web of Science ®Google Scholar
• CainapCQinSHuangWTLinifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trialJ Clin Oncol201533217217925488963
   PubMed Web of Science ®Google Scholar
• ZhuAXRosmorducOEvansTRSEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinomaJ Clin Oncol201533655956625547503
   PubMed Web of Science ®Google Scholar
• LlovetJMLiver cancer: time to evolve trial design after everolimus failureNat Rev Clin Oncol201411950650725091613
   PubMed Web of Science ®Google Scholar
• BruixJTakayamaTMazzaferroVSTORM investigatorsAdjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialLancet Oncol201516131344135426361969
   PubMed Web of Science ®Google Scholar
• StrumbergDSchultheisBRegorafenib for cancerExpert Opin Investig Drugs2012216879889
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• DemetriGDReichardtPKangYKGRID study investigatorsEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986329530223177515
   PubMed Web of Science ®Google Scholar
• BruixJTakWYGasbarriniARegorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicenter, open-label, phase II safety studyEur J Cancer201349163412341923809766
   PubMed Web of Science ®Google Scholar
• BruixJMerlePGranitoAEfficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trialAnn Oncol201627suppl 2LBA03
   Google Scholar
• SchlumbergerMTaharaMWirthLJLenvatinib versus placebo in radioiodine-refractory thyroid cancerN Engl J Med2015372762163025671254
   PubMed Web of Science ®Google Scholar
• IkedaMOkusakaTMitsunagaSSafety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinomaClin Cancer Res20162261385139426500236
   PubMed Web of Science ®Google Scholar
• FuchsCSTomasekJYongCJREGARD Trial InvestigatorsRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialLancet20143839911313924094768
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKVan CutsemERAINBOW Study GroupRamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• ZhuAXParkJORyooBYREACH Trial InvestigatorsRamucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialLancet Oncol201516785987026095784
   PubMed Web of Science ®Google Scholar
• MichalopoulosGKDe FrancesMCLiver regenerationScience1997276530960669082986
   PubMed Web of Science ®Google Scholar
• HuelskenJVogelRErdmannBβ-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skinCell2001105453354511371349
   PubMed Web of Science ®Google Scholar
• GherardiEBirchmeierWBirchmeierCVande WoudeGTargeting MET in cancer: rationale and progressNat Rev Cancer20121228910322270953
   PubMed Web of Science ®Google Scholar
• KondoSOjimaHTsudaHClinical impact of c-Met expression and its gene amplification in hepatocellular carcinomaInt J Clin Oncol201318220721322218908
   PubMed Web of Science ®Google Scholar
• EathirajSPalmaRVolckovaEDiscovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein auto-phosphorylation by ARQ 197J Biol Chem201128623206662067621454604
   PubMed Web of Science ®Google Scholar
• MunshiNJeaySLiYARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activityMol Cancer Ther2010961544155320484018
   PubMed Web of Science ®Google Scholar
• SantoroARimassaLBorbathITivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyLancet Oncol2013141556323182627
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther201110122298230821926191
   PubMed Web of Science ®Google Scholar
• EliseiRSchlumbergerMJMüllerSPCabozantinib in progressive medullary thyroid cancerJ Clin Oncol201331293639364624002501
   PubMed Web of Science ®Google Scholar
• SmithMRDe BonoJSCoraNFinal analysis of COMET-1: cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)J Clin Oncol201533suppl 7abstr139 abstract
   Web of Science ®Google Scholar
• VerslypeCCohnALKelleyRKActivity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II random-ized discontinuation trial (RDT)J Clin Oncol2012304007 abstract
   Google Scholar
• OquiñenaSGuillen-GrimaFIñarrairaeguiMZozayaJMSangroBSpontaneous regression of hepatocellular carcinoma: a systematic reviewEur J Gastroenterol Hepatol200921325425719279469
   PubMed Web of Science ®Google Scholar
• WangZKeZFLuXFThe clue of a possible etiology about spontaneous regression of hepatocellular carcinoma: a perspective on pathologyOnco Targets Ther2015839540025709471
   PubMed Web of Science ®Google Scholar
• PalmerDHMidgleyRSMirzaNA phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinomaHepatology200949112413218980227
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• SangroBGomez-MartinCde la MataMA clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis CJ Hepatol2013591818823466307
   PubMed Web of Science ®Google Scholar
• DuffyAGMakarova-RusherOVPrattDTremelimumab: a monoclonal antibody against CTLA-4 – in combination with subtotal ablation (trans catheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC)J Clin Oncol201634supplabstr4073
   Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• MelcherAParatoKRooneyCMBellJCThunder and lightning: immunotherapy and oncolytic viruses collideMol Ther20111961008101621505424
   PubMed Web of Science ®Google Scholar
• JebarAHErrington-MaisFVileRGSelbyPJMelcherAAGriffinSProgress in clinical oncolytic virus-based therapy for hepatocellular carcinomaJ Gen Virol201596pt 71533155025711964
   PubMed Web of Science ®Google Scholar
• HeoJBreitbachCJMoonASequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyMol Ther20111961170117921427706
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med201319332933623396206
   PubMed Web of Science ®Google Scholar